Lotus Pharmaceutical Co Ltd (1795) — Capital Reinvestment Ratio

Latest as of December 2025: 1.19x

Lotus Pharmaceutical Co Ltd (1795) has a Capital Reinvestment Ratio of 1.19x as of December 2025, meaning it reinvests 1% of its operating cash flow (NT$1.35 Billion) in capital expenditures (NT$1.60 Billion). See Lotus Pharmaceutical Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

1.19x
Capex / Operating Cash Flow

Operating Cash Flow

NT$1.35 Billion
TWD

Capital Expenditures

NT$1.60 Billion
TWD

Data as of

Dec 2025
Most recent filing

Lotus Pharmaceutical Co Ltd Capital Reinvestment Ratio (2009–2025)

This chart tracks Lotus Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 13 annual periods.

Annual Capital Reinvestment Ratio for Lotus Pharmaceutical Co Ltd (2009–2025)

Year-by-year Capital Reinvestment Ratio for Lotus Pharmaceutical Co Ltd from 2009 to 2025. For live market cap and broader valuation context, see 1795 company net worth.

Year Reinvestment Ratio Operating CF (TWD) Capital Expenditures YoY Change
2025 0.58x NT$7.48 Billion NT$4.35 Billion ▲ +144.4%
2024 0.24x NT$6.15 Billion NT$1.47 Billion ▼ -88.3%
2023 2.03x NT$1.61 Billion NT$3.28 Billion ▲ +1207.5%
2022 0.16x NT$3.72 Billion NT$577.16 Million ▼ -98.9%
2021 13.50x NT$119.66 Million NT$1.62 Billion ▲ +1217.2%
2020 1.03x NT$1.95 Billion NT$2.00 Billion ▼ -71.9%
2019 3.64x NT$302.81 Million NT$1.10 Billion ▲ +627.3%
2018 0.50x NT$796.98 Million NT$399.07 Million ▼ -67.6%
2017 1.54x NT$592.29 Million NT$914.84 Million ▲ +188.3%
2016 0.54x NT$1.23 Billion NT$660.48 Million ▲ +10.9%
2015 0.48x NT$1.08 Billion NT$520.71 Million ▼ -80.6%
2010 2.49x NT$59.19 Million NT$147.57 Million ▲ +786.5%
2009 0.28x NT$89.50 Million NT$25.17 Million —
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow